跳至主要内容
临床试验/NL-OMON48085
NL-OMON48085尚未招募不适用

ASICS trial: Avoiding Sentinel lymph node biopsy In select Clinical node negative breast cancer patients after neoadjuvant Systemic therapy - ASICS trial

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 340 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
340

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Women, aged >= 18 years
  • Invasive HER2-positive (Hormone receptor +/-) or triple negative breast cancer
  • Primary tumor (T), clinical stage T1-3
  • Neoadjuvant systemic therapy (NST), at least 3 cycles
  • Tumor stage assessed with breast MRI before start NST
  • Clinically node negative before start NST (no suspect axillary lymph nodes on
  • ultrasound and
  • FGD-PET/CT, or negative cyto-/histopathology in case of suspect nodes)
  • MRI after or during NST shows radiologic complete response
  • Written and signed informed consent

排除标准

  • Primary tumor (T) clinical stage T4
  • Patients without ultrasound or FDG-PET/CT pre-NST
  • History of breast cancer ipsilateral breast
  • Synchronous contralateral breast cancer
  • Synchronous metastatic disease

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验